Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
 

ETFS Holding Keryx Biopharmaceuticals, Inc.

Stock Quotes for Keryx Biopharmaceuticals, Inc. (1)
News Articles for Keryx Biopharmaceuticals, Inc. (19)
 
Stock Quotes for Keryx Biopharmaceuticals, Inc. top ^
kerx - Keryx Biopharmaceuticals, Inc.
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Distressed
View Price Quote for kerx - Keryx Biopharmaceuticals, Inc.
Sign-up for kerx investment picks

 
News Articles for Keryx Biopharmaceuticals, Inc. top ^
2013/3/11
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Keryx to Host Investor Conference Call Tomorrow, Tuesday, March 12, 2013 at 8:30am EDT NEW YORK , March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012 .
View more Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results analysis
Sign-up for Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results investment picks
2013/3/11
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Investor Conference Call to be held Tomorrow, Tuesday, March 12, 2013 at 8:30am EDT NEW YORK , March 11, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held tomorrow, Tuesday, March 12, 2013 at 8:30 a.m. EDT to discuss the Company's fourth quarter and year-end 2012 financial results and provide a business outlook for 2013.
View more Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results analysis
Sign-up for Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results investment picks
2013/3/8
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Upcoming Deadline - KERX
NEW YORK, March 8, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (Nasdaq:KERX) and certain of its officers.
View more SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Upcoming Deadline - KERX analysis
Sign-up for SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders of Keryx Biopharmaceuticals, Inc. of Upcoming Deadline - KERX investment picks
2013/2/6
Keryx Biopharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor, LLP announce that a federal class action lawsuit has been filed against Keryx Biopharmaceuticals, Inc. (“Keryx” or “Company”) (NasdaqCM: KERX). The firms are investigating additional legal claims against the officers and Board of Directors of Keryx during the period of June 1, 2009 to April 1, 2012 (the “Class Period”). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at zach@powerstaylor.com .
View more Keryx Biopharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors analysis
Sign-up for Keryx Biopharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
2013/2/5
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position -- KERX
NEW YORK, Feb.
View more Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position -- KERX analysis
Sign-up for Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position -- KERX investment picks
2013/2/5
Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Keryx Biopharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the April 2, 2013 Lead Plaintiff Deadline
STEVENSON, Md., Feb.
View more Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Keryx Biopharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the April 2, 2013 Lead Plaintiff Deadline analysis
Sign-up for Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in Keryx Biopharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the April 2, 2013 Lead Plaintiff Deadline investment picks
2013/2/1
Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX
NEW YORK , Feb.
View more Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX analysis
Sign-up for Faruqi & Faruqi, LLP Files Class Action Lawsuit Against Keryx Biopharmaceuticals, Inc. -- KERX investment picks
2013/2/13
Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving magicJack VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals
http://media.marketwire.com/attachments/200905/437821_holzerlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=985507&ProfileId=051205&sourceType=1 ATLANTA, GA --
View more Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving magicJack VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals analysis
Sign-up for Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors of Upcoming Deadlines in Shareholder Litigation Involving magicJack VocalTec LTD., Tellabs, Inc. and Keryx Biopharmaceuticals investment picks
2013/1/30
Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
NEW YORK , Jan.
View more Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock analysis
Sign-up for Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock investment picks
2013/2/22
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
Presentation Scheduled for Wednesday, February 27th at 2:15 PM ET NEW YORK , Feb.
View more Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference analysis
Sign-up for Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference investment picks
2013/2/8
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
NEW YORK , Feb.
View more Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm analysis
Sign-up for Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm investment picks
2013/2/8
Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.
NEW YORK , Feb.
View more Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc. analysis
Sign-up for Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc. investment picks
2013/2/7
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position
http://media.marketwire.com/attachments/201107/5424_LeviAndKorsinsky_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=983434&ProfileId=051205&sourceType=1 NEW YORK, NY --
View more Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position analysis
Sign-up for Levi & Korsinsky Notifies Investors With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position investment picks
2013/3/13
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
NEW YORK , March 13, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Amit Sharma , M.D. to the newly created position of Vice President, Medical Affairs.
View more Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs analysis
Sign-up for Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs investment picks
2013/3/18
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Keryx Biopharmaceuticals, Inc. to Contact the Firm -- KERX
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (Nasdaq:KERX) .
View more Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Keryx Biopharmaceuticals, Inc. to Contact the Firm -- KERX analysis
Sign-up for Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Keryx Biopharmaceuticals, Inc. to Contact the Firm -- KERX investment picks
2013/3/18
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) (Nasdaq: KERX) stock between June 1, 2009 and April 1, 2012.
View more SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position analysis
Sign-up for SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position investment picks
2013/3/14
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Presentation Scheduled for Monday, March 18th at 10:00 AM PT NEW YORK , March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be held March 17 th -20 th in Dana Point, California .
View more Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference analysis
Sign-up for Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference investment picks
2013/3/19
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position
NEW YORK , March 19, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (Nasdaq: KERX) stock between June 1, 2009 and April 1, 2012 .
View more SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position analysis
Sign-up for SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of April 2, 2013 to Seek a Lead Plaintiff Position investment picks
2013/3/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX
NEW YORK, March 22, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (Nasdaq:KERX) and certain of its officers.
View more SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX analysis
Sign-up for SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Keryx Biopharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- KERX investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
ETFS Holding Keryx Biopharmaceuticals, Inc.
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Articles by:
Title |  Date |  Author |  Collection |  Interest |  Popularity
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Keppel Corp Ltd  |  Next: ETFS Holding Keycorp
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.